Axon's record Q2 and raised outlook drive growth story
Record Q2 revenue and raised full-year outlook Axon reported Q2 revenue of $904 million, up 35% year over year, and raised its 2026 revenue growth guidance to 32-34% from 30-32%. This shows strong demand for its products and boosts investor confidence in future growth.
This is the core new event that directly lifts Axon's growth prospects and stock price.
Strong bookings and recurring revenue Future contracted bookings jumped 41% to $15.1 billion, and annual recurring revenue rose 39% to $1.6 billion with net revenue retention at 126%. This means customers are committing to more Axon products and services, providing predictable future income.
It highlights the underlying demand strength that supports the raised outlook and long-term growth.
Q2 earnings miss and margin pressure Despite revenue growth, adjusted earnings per share of $1.88 missed the consensus estimate of $1.89, and net income fell to $29 million from $36 million a year earlier. This shows costs are rising and profitability is under pressure, which can weigh on the stock.
It provides the main counterweight to the positive revenue news and explains why the stock dropped after earnings.
New Taser product (Apollo) on track Axon is close to finalizing its Apollo cartridge, a new Taser designed to outperform a nine-millimeter bullet, with a target release by next winter. This innovation could open new markets and drive future sales.
It is a new product development that supports the long-term growth narrative beyond current results.